由HLA - B44呈递的MAGE - 3肽也能被HLA - B18上的细胞溶解性T淋巴细胞识别。

A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18.

作者信息

Bilsborough J, Panichelli C, Duffour M-T, Warnier G, Lurquin C, Schultz E S, Thielemans K, Corthals J, Boon T, van der Bruggen P

机构信息

Immunex Corperation, Seattle, WA, USA.

出版信息

Tissue Antigens. 2002 Jul;60(1):16-24. doi: 10.1034/j.1399-0039.2002.600103.x.

DOI:10.1034/j.1399-0039.2002.600103.x

PMID:12366779

Abstract

Antigens encoded by MAGE genes are of particular interest for cancer immunotherapy because of their tumoral specificity and because they are shared by many tumors. Antigenic peptide MEVDPIGHLY, which is encoded by MAGE-3 and is known to be presented by human leukocyte antigen (HLA)-B44, is currently being used in therapeutic vaccination trials. We report here that a cytolytic T lymphocyte (CTL) clone, which is restricted by HLA-B1801, recognizes the same peptide and, importantly, lyzes HLA-B18 tumor cells expressing MAGE-3. These results imply that the use of peptide MEVDPIGHLY can now be extended to HLA-B18 patients. We also provide evidence that, under limiting amounts of protein MAGE-3, HLA B1801 and B*4403 compete for binding to the peptide.

摘要

由于MAGE基因编码的抗原具有肿瘤特异性且为许多肿瘤所共有，因此它们在癌症免疫治疗中备受关注。由MAGE-3编码且已知可由人类白细胞抗原（HLA）-B44呈递的抗原肽MEVDPIGHLY，目前正用于治疗性疫苗试验。我们在此报告，一个受HLA-B1801限制的细胞毒性T淋巴细胞（CTL）克隆识别相同的肽，并且重要的是，它能裂解表达MAGE-3的HLA-B18肿瘤细胞。这些结果表明，肽MEVDPIGHLY的应用现在可以扩展到HLA-B18患者。我们还提供证据表明，在MAGE-3蛋白量有限的情况下，HLA B1801和B*4403会竞争与该肽的结合。